Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The WHO classification of MDS does make a difference.

Robert B Howe1, Anna Porwit-MacDonald, Robert Wanat

  • 1Division of Hematology, Oncology and Transplantation, University of Minnesota, Mayo Mail Code 480, 420 Delaware St SE, Minneapolis, MN 55455, USA. howex001@umn.edu

Blood
|December 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression.

Molecular oncology·2026
Same author

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.

British journal of haematology·2026
Same author

An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome.

Nature communications·2025
Same author

Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia.

Nature communications·2025
Same author

Stable clonal contribution of lineage-restricted stem cells to human hematopoiesis.

Nature genetics·2025
Same author

SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.

Leukemia·2025

The World Health Organization (WHO) classification for myelodysplastic syndromes (MDSs) is reliable and predicts treatment response. It differentiates subtypes like RARS and RCMD/RS, impacting survival outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Myelodysplastic syndromes (MDSs) are a group of clonal hematopoietic stem cell disorders.
  • Accurate classification is crucial for predicting prognosis and guiding treatment.
  • The World Health Organization (WHO) classification system is widely used for MDS diagnosis.

Purpose of the Study:

  • To assess the interobserver reliability of the WHO classification for myelodysplastic syndromes (MDSs).
  • To determine if the WHO classification predicts clinical response to growth factor therapy.
  • To evaluate the prognostic value of WHO subtypes in low-risk MDS.

Main Methods:

  • Review of 103 previously diagnosed low-risk MDS cases by multiple observers.
  • Analysis of interobserver agreement for the WHO classification.

Related Experiment Videos

  • Correlation of WHO classification with therapeutic response in patients treated with G-CSF and erythropoietin (Epo).

    • Main Results:

    • High interobserver agreement (92%) was found for the WHO classification of MDSs (P <.001).
    • The WHO classification reliably predicted therapeutic response to G-CSF and Epo.
    • Significant differences in response rates were observed between refractory anemia with ringed sideroblasts (RARS) and refractory anemia with multilineage dysplasia and ringed sideroblasts (RCMD/RS) (75% vs. 9%; P =.003).
    • Patients with unilineage dysplasia had longer median survival than those with multilineage dysplasia (P =.03).

    Conclusions:

    • The WHO classification of MDSs demonstrates high reliability among observers.
    • The WHO classification is a valuable tool for predicting treatment response to growth factors.
    • WHO-defined subtypes have prognostic implications for survival in low-risk MDS patients.